Introduction SUMO (small ubiquitin-like modifier) has emerged as a major regulator of a host of cellular processes, and the number of targeted proteins is constantly growing (Geiss-Friedlander and Melchior, 2007) . Covalent conjugation of SUMO to nuclear factors mainly suppresses their activity and/or ability to synergize with other factors, alters their localization and interaction repertoire or increases their stability (Gill, 2005; Hay, 2005; Kerscher et al., 2006) . With the increasing number of sumoylated targets, and the common assumption that the effects of SUMO must be mediated through protein interactions, the identification of a protein motif for noncovalent SUMO binding was awaited. In 2004, Song et al. showed using NMR that a small hydrophobic patch, V/I-X-V/I-V/I, was the minimal motif needed for SUMO interaction (Song et al., 2004) . This only partly matched a motif proposed earlier (Minty et al., 2000) . However, with the work of Hannich et al. (2005) and Hecker et al. (2006) , the suggested consensus sequences were harmonized to V/I-X-V/I-V/Ia-a-a (a ¼ acidic). Furthermore, the motif was shown to be able to bind to SUMO when reversed Hecker et al., 2006) . The discovery of SUMOinteracting motifs (SIMs) has provided new insight into the interplay between sumoylation and SUMO binding, with the tumor suppressor PML as one of the beststudied examples Shen et al., 2006; Lallemand-Breitenbach et al., 2008) . The PML protein contains both sumoylation motifs and SIMs, and both motifs must be intact to form PML nuclear bodies (Shen et al., 2006) . c-Myb is a sequence-specific transcription factor that controls proliferation and differentiation of early hematopoietic progenitor cells, as well as regulating similar processes in colonic crypts and neurogenic regions of the adult brain (Ramsay and Gonda, 2008) . The MYB locus is rearranged in several human neoplasias, with increased expression as a frequent outcome. This can be caused by translocation, leading to deregulation of the MYB gene, as in childhood T-cell acute lymphoblastic leukemia (Clappier et al., 2007) , or stabilization of MYB mRNA, as in adenoid cystic carcinomas of the breast, head and neck (Persson et al., 2009) . Local duplication of MYB has also been reported with another subgroup of T-cell acute lymphoblastic leukemia (Clappier et al., 2007; Lahortiga et al., 2007) and in a subgroup of acute myelomonocytic leukemia (Murati et al., 2009) . Thus, deregulation of c-Myb expression is associated with oncogenicity. Moreover, the transcriptional regulatory activity of Myb is crucial for its transforming ability (Gonda et al., 1989; Lane et al., 1990; Hu et al., 1991) . Multiple co-factors like p300/CBP, Mi-2a, FLASH and menin/MLL engage in the regulation of the transactivational activity of c-Myb (Dai et al., 1996; Oelgeschlager et al., 1996; Kasper et al., 2002; Saether et al., 2007; Alm-Kristiansen et al., 2008; Jin et al., 2010) . Recently, the importance of coactivation by p300 in myeloid transformation was highlighted using a novel murine hematopoietic cell line transformation assay (Pattabiraman et al., 2009) . Moreover, the interaction between Myb and menin/MLL has been shown to be a critical driver in MLL-associated leukemogenesis (Jin et al., 2010) .
c-Myb becomes sumoylated in its C-terminal regulatory domain (CRD) at two sites, by both SUMO1 and SUMO2/3. This leads to a severe drop in the activity of c-Myb (Bies et al., 2002; Dahle et al., 2003; Sramko et al., 2006) . We have recently shown that this drop in activity is mainly caused by silencing of a SUMOregulated activation function in CRD, severely reducing the synergistic potential of c-Myb (Molvaersmyr et al., 2010) . In the oncogenic v-Myb protein, both SUMO conjugation sites are deleted and synergy control is lost. Whether loss of SUMO regulation is a central step in oncogenic activation of c-Myb has so far not been addressed.
In this article, we show that the transactivation potential of c-Myb is modulated not only through SUMO conjugation, but also through noncovalent SUMO binding. We have identified a functional SIM in the transactivation domain of c-Myb, which preferentially binds SUMO2/3. Abrogation of SUMO binding through mutation leads to an increase in c-Myb transactivational activity, mainly caused by lost repression in trans. Through the use of hematopoietic transformation assays, we show that loss of SUMO regulation can oncogenically activate c-Myb. However, only loss of SUMO binding, and not SUMO conjugation, unleashes the transforming potential of c-Myb.
Results
c-Myb contains two putative SUMO-interacting motifs AMV v-Myb is one of two oncogenically activated forms of c-Myb known to cause acute leukemia in chickens. Deletions in the v-myb gene eliminate the CRD (Figure 1a) , making v-Myb behave like an activated form of c-Myb in many assays with lost SUMO conjugation playing a key role (Dahle et al., 2003) . We recently realized that loss of SUMO conjugation sites might not be the only oncogenic alteration in v-Myb that relates to SUMO biology. On the basis of reports of a consensus SIM (aaa-V/I-V/I-X-V/I/L and V/I-X-V/I-V/I-aaa; Song et al., 2004; Hecker et al., 2006) , we analyzed the c-Myb sequence and found that it contains two putative SIMs; one in the R2 repeat in the DNAbinding domain (M1), and one in the N-terminal end of the transactivation domain (M2; Figures 1a and b) . Both sites are evolutionarily well conserved, and remarkably, both are mutated in AMV v-Myb (Figure 1b) . In fact, three of the ten oncogenic mutations in v-Myb are localized to the putative SIMs. The specificity of noncovalent SUMO1 vs SUMO2 binding lies in a stretch of negatively charged residues located directly N-or C-terminally of the core SIM motif . The fact that only M1 has such neighboring residues implies that if functional, the cMyb M1 would be a SUMO1-interacting motif, whereas M2 would mainly interact with SUMO2/3.
Destroying the putative SIM in the transactivation domain by mutations derepresses c-Myb To investigate whether mutations in these potential SIMs would influence c-Myb activity, we made a set of mutants aiming to abrogate SUMO binding (Figure 1c) . The mutants L106H and I 267 NII were generated to mimic the mutations found in v-Myb M1 and M2, respectively. However, as only the L106H mutation represented a deviation from the SIM consensus, additional mutations A 103 AEA (wild-type: V 103 IEL) and A 267 NAA (wild-type: V 267 NIV) were introduced We then performed effector-reporter assays using a c-Myb-responsive luciferase reporter. As can be seen in Figure 2a , the M1 mutant L106H had no effect, whereas the A 103 AEA appeared to have a slight negative influence on c-Myb-mediated transactivation. However, the A 267 NAA M2 mutant had a dramatic effect and activated c-Myb more than 13-fold relative to the wild type. The activity of this mutant closely resembled that of the SUMO conjugation-negative 2KR mutant (Dahle et al., 2003) , used as a positive control (Figure 2a) . The v-Myb mimicking mutation I 267 NII had no such derepression effect; rather, it slightly lowered the activity of c-Myb. As can be seen in Figure 2b , none of these effects can be attributed to mutation-induced changes in protein expression levels. It therefore appears that the V 267 NIV motif in c-Myb TAD has a strong suppressive function on activity, possibly mediated through the binding of SUMO, and that the A 267 NAA mutant abrogates this suppression.
Human c-Myb binds SUMO through a SIM in the transactivation domain To examine whether c-Myb was able to bind SUMO, we asked whether c-Myb could be pulled down from cell lysates using GST-SUMO1 and -SUMO2. This is currently one of the most stringent ways of detecting SUMO interactions, allowing both endogenous SUMO and SUMO-binding factors to compete for epitopes. SUMO, in general, binds to SIMs with affinities in the mM range , making the interaction somewhat difficult to detect. To avoid potential interference from SUMO moieties conjugated to c-Myb, we used a shortened version of human c-Myb (aa 1-409) where the CRD (harboring the SUMO conjugation motifs) had been deleted. As can be seen in Figure 3a , c-Myb bound SUMO under these conditions. Furthermore, it seemed to interact more efficiently with SUMO2 than with SUMO1.
To determine which of the motifs might be responsible for the noncovalent binding of SUMO, we evaluated the different mutants in pull-down assays.
Comparison of wild-type c-Myb with the M1 mutants (L106H and A 103 AEA), did not reveal any difference in the affinity for SUMO ( Figure 3b) ; both proteins interacted with SUMO2, and thus resembled the wild type. In contrast, an obvious difference was observed when comparing the M2 mutants (A 267 NAA and I 267 NII) with the wild-type (Figure 3c ). Whereas the I 267 NII mutant seemed to have retained the ability of c-Myb to bind SUMO, the A 267 NAA mutant had lost this property. Importantly, we could also show that fulllength c-Myb, like the shorter version, was retained with GST-SUMO2 ( Figure 3d ). Moreover, the M2 mutation ANAA lowered the affinity for SUMO2 substantially. Finally, we tried to study the interaction between SUMO and c-Myb, expressed at endogenous levels in erythroleukemia K562 cells. As expected, owing to the low SIM . Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis and immunoblot analysis was performed using an anti-HA antibody.
Abrogating SUMO binding affects sumoylation of c-Myb
The evidence presented above show a physical, noncovalent interaction between SUMO and the c-Myb SIM, V 267 NIV. Moreover, a derepression of c-Myb activity was observed with the A 267 NAA mutant. Because the latter effect resembled that of the SUMO conjugation-disrupting 2KR mutations, we asked whether derepression by the ANAA mutation might be caused by SUMO conjugation being dependent on a functional SIM as previously shown for TDG, Daxx and SP100 (Takahashi et al., 2005; Lin et al., 2006; Knipscheer et al., 2008) . The two SIM mutants (A 267 NAA and I 267 NII) were expressed in CV-1 cells in absence or presence of the SUMO E2-conjugating enzyme Ubc9 or the SUMO E3 ligase PIASy, increasing the relative amount of sumoylated c-Myb, and the sumoylation patterns were compared with those of wild type c-Myb (two mono-þ one disumoylated form) and 2KR (no sumoylated forms) ( Figure 4 ). As can be seen in Figure 4 , the level of sumoylated c-Myb was lowered , wildtype and ANAA. The lysate was incubated with comparable amounts of GST-SUMO1 and -SUMO2 fusion proteins. The bound proteins were analyzed by SDS-polyacrylamide gel electrophoresis and immunoblot analysis using an anti-FLAG antibody. 5% of the input (total cell extract) used for the pull-down was loaded as reference. The amount of GST and GST fusion proteins was evaluated with Ponceau S red staining of the membrane after immunoblotting. Cells were scraped in cold phosphate-buffered saline and lysed directly by sonication in SDS loading buffer. The lysates were subjected to SDS-polyacrylamide gel electrophoresis and immunoblot analysis using an anti-HA antibody. PIASy was visualized using an anti-T7 antibody.
when the SIM consensus was lost (ANAA). The INII mutant on the other hand seemed to be sumoylated with the same efficiency as wild-type c-Myb. The reduced sumoylation efficiency observed with the ANAA mutant was persistent and could be seen when both E2 and E3 were overexpressed (Figure 4) . Nevertheless, c-Myb ANAA was modified, although at lower levels; this contrasts with c-Myb 2KR where SUMO conjugation was lost. We conclude that SUMO binding has a modulating effect on SUMO conjugation, without it being able to explain the high transactivational activity of the ANAA mutant.
Functional effects of altered SUMO interaction in the absence of SUMO conjugation Previous studies have reported the existence of intramolecular interactions between the EVES domain and the N-terminal region of c-Myb (Dash et al., 1996) . Moreover, others have speculated that there might be an indirect contact between the CRD and the TAD (Dubendorff et al., 1992; Vorbrueggen et al., 1994) . Thus, we asked whether SUMO conjugates in the CRD and the SIM in the TAD might interact to bridge these parts of c-Myb. We reasoned that if SUMO conjugation and SUMO binding were part of the same mechanism in c-Myb, destroying either one or both of these functions would lead to a similar enhancement of transactivation. As shown in Figures 2a and 5a , c-Myb A 267 NAA and c-Myb 2KR possess almost identical activities. However, when both these mutations were introduced in the same construct (c-Myb ANAA 2KR), an additive increase in activity was observed (Figure 5a ), arguing against these two mutants targeting the same mechanism. Even when the entire CRD was deleted, the A 267 NAA mutation still increased the activity of c-Myb (Figure 5b) . Thus, we conclude that the transactivation potential unleashed by the SIM mutation in c-Myb is disconnected from SUMO conjugation in the EVES domain. Even though the SIM might be involved in recruiting or orienting components of the sumoylation apparatus, the SIM clearly also has a conjugation-independent function.
To make sure that what we had observed so far was also relevant for regulation of c-Myb-dependent activation of endogenous chromatin-embedded genes, we tested the mutants for their ability to activate mim-1 (Burk et al., 1993; Ness et al., 1993) , using real-time PCR. Mutation of the SIM in c-Myb resulted in significant increase in expression of mim-1, both alone and in combination with the 2KR mutation (Figure 5c ). To ensure that the increased transactivational activity of the SUMO binding mutant was not caused by altered DNA-binding activity, we analyzed the promoter occupancy of c-Myb on the established target gene, MYC, using chromatin immunoprecipitation. Neither the ANAA, nor the 2KR mutations, changed the ability of c-Myb to occupy the MYC promoter (Supplementary  Figure 4) . Together, this confirms a role for c-Myb SUMO binding in endogenous gene activation.
c-Myb binds SUMO in trans in a SIM-dependent manner Because our data obtained with double mutations and CRD deletions did not support the hypothesis of intramolecular binding of SUMO, we predicted that the SIM had to bind SUMO in trans and that its 
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T Saether et al repressive effect could be attributed to the recruitment of sumoylated, negatively acting co-factor(s). If so, it should be possible to titrate out this co-repressor with an excess of free SUMO, and thereby increase Myb activity. Thus, we expressed increasing amounts of nonconjugatable SUMO1 and -2 (mono-Gly in C terminus) in the presence of our c-Myb mutants. We expected the nonconjugatable SUMO to interfere mainly with SUMO binding, but also indirectly with conjugation, as the conjugation process is dependent on SUMO interactions (Reverter and Lima, 2005; Tatham et al., 2005) . As can be seen in Figure 6a , co-expression of SUMO1-1G in the presence of wild-type c-Myb led to an increase in transactivation, whereas no significant change in activity was observed for c-Myb ANAA 2KR. The derepression of wild-type c-Myb was even more pronounced when titrating in increasing amounts of SUMO2-1G (Figure 6b) , consistent with the observed preference for SUMO2. Interestingly, a reduced responsiveness was observed for c-Myb ANAA as well as for c-Myb 2KR, indicating that both proteins are partly uncoupled from SUMO-mediated repression. For c-Myb ANAA, the reduced responsiveness is most probably caused by lost SUMO binding, whereas the residual induction may be caused by the SUMO-1Gs interfering with sumoylation. For the 2KR mutant the situation is reversed, and the remaining ability to be induced must be due to SUMO-1Gs titrating out SUMO-binding factors.
As an alternative approach we also co-transfected our SUMO contact mutants together with plasmids expressing the SUMO-specific protease SENP1. The rationale was that SENP1 would desumoylate both c-Myb and other (co-)factors. SENP1 would therefore relax both SUMO binding-and conjugation-dependent repression of c-Myb activity. As shown in Figure 6c co-transfection led to an increase in activity for wild-type c-Myb, which was not observed with the catalytically dead SENP1 mutant. Moreover, both ANAA and 2KR mutants showed reduced potential for SENP1-induced activity. Importantly, only the double mutant, ANAA 2KR, was inert to the effects of desumoylation. Taken together these data strongly suggest that c-Myb binds SUMO in trans, probably in the form of a sumoylated co-repressor. This factor may be titrated out with free SUMO, with SUMO2 being the most efficient competitor due to its higher affinity for c-Myb.
We also investigated whether broken SUMO contacts might change the distribution of c-Myb. However, both in the absence and in the presence of PML IVa, a potential sumoylated co-repressor, inducing PML NBs, neither loss of SUMO-binding, nor SUMO-conjugation properties affected the subcellular localization of c-Myb or its recruitment to PML-NBs (Supplementary Figure 5) .
Proliferation and differentiation properties of the SUMO contact mutants
To better understand the biological consequences of lost SUMO binding and conjugation, we investigated the transforming abilities of our c-Myb mutants. To this end we took advantage of a newly established murine hematopoietic cell line transformation assay of at least three independent assays performed in triplicates. (Pattabiraman et al., 2009) . FDB-1 is a factor-dependent cell line that proliferates in the presence of interleukin-3 (IL-3) and differentiates into granulocytes and macrophages within 7 days in the presence of granulocyte macrophage colony-stimulating factor (GM-CSF; McCormack and Gonda, 2000) . c-Myb can, however, block terminal differentiation of this cell line induced by GM-CSF (Brown et al., 2006) , leading to continuous proliferation. We transduced FDB-1 cells with the GFPtagged SUMO contact Myb mutants. The cells were then sorted for GFP expression before they were used to assay proliferation and differentiation properties. For control purposes the expression level and transactivational activity of the different Myb variants were validated by immunoblotting (Supplementary Figure 6) and effector-reporter assay (Supplementary Figure 7) , respectively.
As described before, cells transduced with wild-type cMyb and c-Myb CT3 proliferated continuously in the presence of GM-CSF ( Figure 7a ). As expected, the empty-vector-transduced cells lost their capacity to proliferate following stimulation with GM-CSF. Interestingly, the cells transduced with c-Myb ANAA and ANAA 2KR showed very rapid proliferation (with the latter reproducibly slightly higher than the former) compared with either wild-type or CT3 Myb, whereas the cells transduced with c-Myb 2KR behaved much like the wild-type Myb-transduced cells (Figure 7a) .
To examine the effects of the SUMO contact mutants on differentiation of FDB-1 cells, we assessed morphology by May-Grunwald-Giemsa staining following culture in GM-CSF for 7 days (Figures 7b and c) . As reported earlier, c-Myb-transduced FDB-1 cells showed a larger number of undifferentiated blast-like cells when compared with empty-vector-transduced cells (Figure 7b ). Myeloblasts made up approximately 30% of the cells with both c-Myb wild-type and CT3, representing a 10-fold increase compared with the empty vector control. An even more pronounced differentiation block with up to 50% blasts was observed with the SUMO binding mutants ANAA and ANAA 2KR, whereas the SUMO conjugation-dead 2KR mutant once again generated a differentiation profile similar to wildtype c-Myb (Figure 7b ). We also assayed the expression of the myeloid cell-surface differentiation markers Gr-1 and Mac-1. As seen in Figures 7d and e, and Supplementary Figure 8 , FDB-1 cells transduced with the ANAA and ANAA 2KR mutants showed lower expression of Gr-1 and Mac-1 compared with wild-type Myb, CT3 and 2KR. These differences were, however, not statistically significant, but consistent with the morphological data (Figure 7b ). To confirm the results from the cell line transformation assays, we conducted colony-forming assays using primary hematopoietic cells from murine bone marrow. As shown in Figure 8 , c-Myb wild-type transduced cells formed around 40 colonies per 50 000 cells plated, whereas c-Myb ANAA and ANAA 2KR, as well as CT3, formed almost fourfold more colonies. In contrast, c-Myb 2KR behaved like the wild-type. These results are consistent with the results from FDB-1 assays. Taken together, the transformation assay data imply that the SUMO binding mutants ANAA and ANAA-2KR, but not the SUMO conjugation mutant 2KR, possess enhanced transforming activity compared with wild-type c-Myb.
Discussion
In this work we have identified a novel interaction of human c-Myb with SUMO, mediated by a SIM (V 267 NIV) close to the transactivation domain. This motif is involved in regulating the transactivational potential as well as modulating the SUMO modification of c-Myb. Most importantly, we show that SUMO binding is involved in dampening the transforming activity of this oncoprotein.
The functionality of this motif was assessed by two criteria: (1) c-Myb should show detectable binding affinity for SUMO, dependent on an intact SIM; and (2) removal of SIM by mutation should cause a change in the activity of c-Myb. The first criterion was addressed by GST pull-down assays with different SUMO isoforms and showed that c-Myb binds SUMO in a SIM-dependent manner, with a clear preference for SUMO2/3 (Figure 3) . Second, mutation of the SIM substantially increased transactivation potential of Myb (Figure 2 ). The determinant for SUMO isoform binding preference has been shown to lie in a stretch of negatively charged residues located directly N-or Cterminally of the SIM . Because the SIM in TAD only consisted of a hydrophobic core (closest acidic residue: þ 14), we reasoned that it would be a SUMO2/3-interacting motif, and indeed this was the case: in all the interaction assays we performed a preference for SUMO2 binding was observed (Figure 3) . Still, SUMO1 binding might be functionally important when the modifier is conjugated to the appropriate factor, due to additional contact surfaces (Geiss-Friedlander and Melchior, 2007) .
Our study data may explain previous observations on the effect of linker insertion mutagenesis in AMV v-myb. In studies performed to examine the correlation between transactivation and transformation by v-Myb, Lane et al. (1990) in fact generated one insertion mutant interfering with the SIM element as defined in this work (v-Myb 752; I 202 NII-I 202 NGPII). Interestingly, this mutant was able to activate transcription 25-fold more efficiently than AMV v-Myb in QT6 cells (Chen and Lipsick, 1993) , suggesting that this might be due to loss of interaction with a unknown cellular inhibitor. In light of this present work their data may be explained by disruption of the SIM, hence SUMO binding.
Mechanistically, we would assume that the SIM functions through the interaction with a sumoylated protein, exerting a repressive effect on c-Myb. The most obvious alternative would be an intermolecular mechanism, where a SUMO-modified co-repressor would bind to the SIM. An alternative hypothesis would be that the SIM interacts intramolecularly with sumoylated c-Myb CRD, leading to a repressed conformation of c-Myb.
The second explanation would potentially substantiate the hypothesis of a fold-back mechanism involving the EVES domain and the N-terminal region in c-Myb (Dash et al., 1996; Karafiat et al., 2001) or the transactivation domain (Dubendorff et al., 1992; Vorbrueggen et al., 1994) . Such intramolecular interactions have been hypothesized to conceal co-activator binding epitopes, thus lowering c-Myb activity. Indeed, the comparable activities of c-Myb 2KR and ANAA (Figures 2a and 5a ) are consistent with a common SUMO binding and the transforming ability of c-Myb T Saether et al mechanism, representing two ways of destroying the same intramolecular bridge. However, when introducing both mutations in the same construct, the transcriptional activity doubled (Figure 5a) . Moreover, the ANAA mutant still activated when the CRD, including the SUMO-modified area of c-Myb, was deleted (Figure 5b ). These data are not compatible with a SUMO-governed inhibitory fold-back mechanism in c-Myb, although they do not exclude the possibility of a fold-back mechanism not involving SUMO or not leading to activity changes. In light of these data it is interesting to notice that another type of crosstalk does occur. The SIM in the TAD is involved in fine-tuning the sumoylation of c-Myb in the EVES domain, such that, mutating the SIM reduces the sumoylation of c-Myb slightly (Figure 4a ). Such interdependency has been shown for other SUMO targets, and reflects the fact that noncovalent binding of SUMO is an important mechanistic step in the conjugation reaction, orientating the SUMO moiety for optimal transfer (Reverter and Lima, 2005; Tatham et al., 2005) .
Having ruled out the loss of intramolecular interaction as explanation of the increased transactivational activity of the SIM mutant, we addressed the possibility of intermolecular mechanisms. We reasoned that if a sumoylated factor was binding to c-Myb SIM, it should be possible to block this interaction by overexpressing nonconjugatable SUMO. Doing so, we were able to increase the c-Myb activity, most likely by titrating out SUMO-binding repressors (Figure 6 : wt vs ANAA) and also by decreasing conjugation of SUMO to the sites in CRD through interference with the sumoylation apparatus ( Figure 6 : wt vs 2KR). Thus, c-Myb is repressed in trans through the SIM, as well as through the SUMO moieties in EVES. The identification of SUMO contactdependent co-repressors will be addressed in future work.
As the SUMO field has evolved, several diseases, including cancers, have been linked to perturbations in the SUMO system and/or disruption of sumoylation by mutations in substrate proteins (Hoeller et al., 2006) . Using hematopoietic transformation assays (Pattabiraman et al., 2009), we examined the transforming abilities of the SUMO interaction mutants. Interestingly, only the SUMO binding ANAA mutant seemed to be able to transform hematopoietic cells more effectively than wild-type c-Myb (Figures 7 and 8) . In contrast, the nonconjugatable c-Myb 2KR had the same transforming potential as wild-type Myb, despite both ANAA and 2KR mutants being similarly highly active in transactivation assays. Furthermore, the double mutant ANAA 2KR was hyperactive in transactivation assays but was only marginally more active than ANAA in transforming the FDB1 cells (Figure 7 ). This is surprising because there is generally strong correlation between transactivation and transformation by c-Myb (Hu et al., 1991) , and the importance of functional co-activation by CBP/p300 (Pattabiraman et al., 2009) and menin/MLL (Jin et al., 2010) has been shown. In cancers linked to aberrations involving the MYB locus, increased c-Myb dosage, and hence activity, seems to be a common theme (Clappier et al., 2007; Lahortiga et al., 2007; Persson et al., 2009 ). Nevertheless, the 2KR and ANAA mutants described here seem to partially dissociate transactivation from transformation. Even though both types of SUMO contacts appear to restrict c-Myb activity to the same degree, they clearly differ when it comes to restricting Myb-dependent transformation. Thus, the putative repressor interacting with the SIM in TAD must play a particularly important role. Interestingly, the two factors p300 and MLL, shown to be necessary for promoting transformation by c-Myb, bind within the same region (Pattabiraman et al., 2009; Jin et al., 2010) . Thus, our data on SUMO binding add to the complexity and functional importance of the transactivation domain in c-Myb. It is becoming increasingly apparent that this domain is a sophisticated control region in which the critical functions of c-Myb are regulated through a multiplicity of interactions, balancing activation and transformation.
Materials and methods

Plasmids and antibodies
Information about the plasmids and antibodies used in this work is outlined in Supplementary Information Protein expression and GST pull-down assay GST and GST-SUMO fusion proteins were expressed in Escherichia coli as previously described (Gabrielsen et al., 1991) . GST pull-down was performed with both COS-1 expressed and in vitro translated proteins as described in Supplementary Information. 
